EPIZYME PIPELINE

PROGRAM	TREATMENT APPROACH	POPULATION	RESEARCH	PHASE 1	PHASE 2	PHASE 3	APPROVED
TAZVERIK® (tazemetostat)[a]							
Epithelioid Sarcoma[a]	Monotherapy	Adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.					Approved by US FDA in Jan 2020
Non-Hodgkin Lymphoma[a]	Monotherapy	• Adult patients with relapsed or refractory follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least two prior systemic therapies. • Adult patients with relapsed or refractory FL who have no satisfactory alternative treatment options.					Approved by US FDA in Jun 2020
TAZEMETOSTAT							
Non-Hodgkin Lymphoma	Combination w/ R^2	Follicular lymphoma – 2nd-line+ (vs R^2 alone)				Phase 1b/3 confirmatory trial	
	Combination w/ R-CHOP	Follicular lymphoma – front-line (Lysa)					
	Combination w/ R-CHOP	DLBCL – front-line (Lysa)					
Molecularly Defined Solid Tumors	Combination w/ doxorubicin	Epithelioid sarcoma – front-line (vs doxorubicin alone)				Phase 1b/3 confirmatory trial	
	Combination w/ ASIs	Castration-resistant prostate cancer – (vs ASIs alone)			Phase 1b/2 trial		
	Monotherapy	Pediatrics with INI1-negative tumors					
PRMT INHIBITORS							
PRMT 5 Inhibitor (GSK3326595)[b]		Solid tumors and blood cancers (gsk)					
PRMT 1 Inhibitor (GSK3368715)[b]		Solid tumors and diffuse large B-cell lymphoma (gsk)					

FOOTNOTES:

a. The TAZVERIK® ES & FL indications were approved under accelerated approval. See full U.S. prescribing information at www.TAZVERIK.com

b. GlaxoSmithKline holds global development and commercialization rights

GENERAL NOTES:

Eisai holds rights to tazemetostat in Japan.

R^2 = Revlimid® (lenalidomide, Celgene) + a rituximab product; ASIs = androgen signaling inhibitors

Epizyme™

Not for promotional use.

Updated as of January 29, 2021